Intranasal Oxytocin for the Treatment of Children and Adolescents With Autism Spectrum Disorders (ASD)
Status:
Completed
Trial end date:
2016-03-01
Target enrollment:
Participant gender:
Summary
We are studying an investigational drug called intranasal oxytocin (Syntocinon®). Syntocinon®
has been approved by the U.S. Food and Drug Administration for use in helping women
breastfeed, but it has not been approved for use in children with ASD. However, there is
previous research conducted that has indicated that after administration of oxytocin, adults
with ASD demonstrated improvements in social cognition, and reduced repetitive behaviours and
anxiety. There is also early research to suggest that children may also benefit in these
areas. The purpose of this study is to test if oxytocin works to help children and
adolescents with ASD.